-- Group total revenue increased to RMB 3,701.4 million, representing 37.0% 
      period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] 
      basis) 
 
   -- Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 
      million. Gross profit margin was 37.0%, a 0.9 percentage points increase 
      compared to 2025 1H 
 
   -- Adjusted net profit attributable to owners of the Company increased by 
      37.4% period-over-period, reaching RMB 1,027.3 million. The margin of 
      adjusted net profit attributable to owners of the Company remained stable 
      at 27.8%, a 0.1 percentage increase compared to 2025 1H 
 
   -- The total global customer base expanded to over 810 companies, and 15 out 
      of the TOP 20 global pharmaceutical companies have partnered with us 
 
   -- The total number of iCMC projects reached 328, with 51 newly signed iCMC 
      projects 
 
   -- The commercial and PPQ pipeline: 2 commercial projects; 21 PPQ projects 
      in total, with 2 PPQ projects newly signed in 2026 1H 
 
   -- The service backlog grew to approximately US$2.0 billion, a solid 50.4% 
      increase period-over-period. Including the upcoming milestone fee, total 
      backlog reached approximately US$2.2 billion, up 62.2% period-over-period 
 
([1]) Actual exchange rate 
([2]) Constant exchange rate 
 

SHANGHAI, Aug. 24, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for the six months ended June 30, 2026 (the "Reporting Period").

CEO Comment

Dr. Jimmy Li, CEO of WuXi XDC, stated, "Our strong first-half 2026 performance reflects the continued execution of our long-term strategy and increasing global demand for integrated bioconjugate CRDMO services. During the period, we further strengthened our capabilities through the successful integration of BioDlink, continued expansion of our global manufacturing network, and advancement of our proprietary technology platforms. Looking ahead, we remain committed to empowering customers through our 'Enable, Follow and Win the Molecule' strategy and are well positioned to capture the significant opportunities emerging across the broader XDC market."

Financial Highlights for Interim Results of 2026

Revenue

   -- The Group's revenue increased to RMB 3,701.4 million for the six months 
      ended June 30, 2026, representing 37.0% period-over-period growth on an 
      AER basis (41.5% on a CER basis). 
 
   -- This increase was primarily attributable to (i) the growth in the number 
      of customers and projects, driven by continued active development of the 
      global ADC and broader bioconjugates market, (ii) the increasing market 
      share through the Group's established position as a leading ADC CRDMO 
      service provider in that market, and (iii) the steady advancement of the 
      Group's projects into later stages. 

Gross Profit and Its Margin

   -- The Group's gross profit increased by 40.6 % period-over-period to RMB 
      1,371.3 million, with a gross profit margin of 37.0 % for the six months 
      ended June 30, 2026, a 0.9 percentage points increase compared to that of 
      2025 1H. 
 
   -- This improvement is driven by (i) the continuous enhancement of our 
      overall operation and manufacturing efficiency, (ii) the utilization 
      ratio of production facilities continued to maintain at a high level, 
      mainly due to strong customer demand, (iii) the successful ramp-up of 
      operating production lines, and(iv) increased contribution from higher 
      value-added services. 

Adjusted Net profit attributable to owners of the Company and Its Margin

   -- The Group's adjusted net profit attributable to owners of the Company 
      increased by 37.4% period-over-period to RMB 1,027.3 million, 
      demonstrating the strong profit growth momentum of the Group's core 
      operating business. The margin of adjusted net profit attributable to 
      owners of the Company remained stable at 27.8 % for the six months ended 
      June 30, 2026, a 0.1 percentage points increase compared to that of 2025 
      1H. 
 
   -- This growth and improvement were primarily driven by the factors above 
      and continuous disciplined control of SG&A expenses. 

Customers and Projects Highlights for Interim Results of 2026

   -- We have continuously expanded our customer base, reaching a cumulative 
      total of 814. 
 
   -- The "Enable, Follow, and Win the Molecule" strategy continued to drive 
      sustained and rapid project growth. The total number of integrated 
      projects ("iCMC projects") is 328, with 51 newly signed integrated 
      projects. 
 
   -- The Group has successfully secured 21 PPQ projects, with 2 new PPQ 
      projects signed in 2026 1H. 
 
   -- The Group currently holds 2 commercial-stage projects, demonstrating its 
      emerging track record and proven capabilities in commercial 
      manufacturing. 
 
   -- The Group has a diversified project base covering both innovative ADC and 
      broader bioconjugate ("XDC") projects. The total number of integrated ADC 
      projects reached 286, and the number of integrated XDC projects increased 
      to 42. 
 
   -- In 2026 1H, the Group explored over 3,100 molecules of multiple 
      modalities, including bispecific ADCs, dual-payload ADCs, 
      degrader-antibody conjugates $(DAC)$, antibody-oligonucleotide conjugates 
      (AOC), antibody-peptide conjugates $(APC)$, etc. Notably, the Group 
      explored over 22,000 ADC/XDC molecules cumulatively as at the end of the 
      Reporting Period. 

Development of Fully Integrated R&D Technology Platform During 2026 1H

The Group provides customers with innovative conjugation and payload-linker technologies to accelerate the development of next-generation bioconjugates. Multiple customer programs enabled by the WuXiDARx$(TM)$, X-LinC(TM), and WuXi Payload-Linker(TM) platforms have advanced from PCC to iCMC and clinical development, demonstrating the robustness, scalability, and broad applicability of the Group's integrated technology platform.

WuXiDARx(TM) - Conjugation platform

WuXiDARx(TM) is a clinically validated conjugation platform that enables highly homogeneous ADCs, APCs, AOCs, and dual-payload ADCs, supporting diverse bioconjugate modalities from discovery through clinical development. The platform has successfully facilitated customers bringing 8 ADC pipelines from preclinical stage to clinical stage.

   -- WuXiDAR4(TM) enhances ADC homogeneity and therapeutic index (TI), 
      enabling over 10 iCMC programs, including 8 in clinical development. 
 
   -- WuXiDAR2(TM) delivers highly homogeneous ADCs and APCs, enabling the 
      first DAR2 ADC program advance to iCMC-ready stage. 
 
   -- WuXiDAR1(TM) delivers highly homogeneous DAR1 AOCs, validating the 
      platform for AOC development. 
 
   -- WuXiDARx(TM) technology also enables sequential, precise dual-payload 
      conjugation via native interchain cysteine sites without antibody 
      engineering or enzymatic conjugation, offering a streamlined, 
      cost-effective single-platform solution. The technology has successfully 
      enabled first dual-payload ADC program to iCMC-ready stage. 

WuXi Payload-Linker(TM) - Payload-linker platform

WuXi Payload-Linker(TM) technologies enable next-generation ADCs with differentiated mechanisms of action, improved therapeutic index, and enhanced developability through proprietary payload and hydrophilic linker technologies.

   -- WuXiTecan-2(TM) is a proprietary exatecan-based payload-linker platform 
      featuring improved hydrophilicity, plasma stability, and robust in vivo 
      efficacy. The technology has been successfully applied to 3 iCMC-stage 
      customer programs through technology licensing agreements with Earendil 
      Labs and a European biotech company in 2026, demonstrating its strong 
      developability and translational potential.  Notably, a WuXiTecan-2(TM)- 
      based dual-payload ADC (MMAE + WuXiTecan-2(TM)) successfully achieved PCC 
      and advanced into iCMC development, highlighting the platform's ability 
      to enable next-generation ADC development. 
 
   -- WuXiLinker(TM) is a proprietary hydrophilic linker technology that 
      enables hydrophobic payloads with improved developability, stability, and 
      conjugation performance. The technology has been successfully extended to 
      multiple payloads, including WuXiMMAE(TM), WuXiATRi(TM), and 
      WuXiEribulin(TM), and extended beyond established payloads to support the 
      development of next-generation payload-linker technologies, including DDR 
      inhibitors and other differentiated hydrophobic payloads. 
 
   -- X-LinC(TM) is a proprietary stable conjugation connector that replaces 
      conventional maleimide chemistry, enhancing ADC stability through reduced 
      payload-linker deconjugation and improved in vivo stability.